RTI Biologics has signed an expanded agreement with Davol, a subsidiary of CR Bard.
Under the agreement, RTI will supply Tutoplast for exclusive worldwide distribution by Davol for breast reconstruction applications. The agreement also extends Davol’s exclusive worldwide distribution rights for dermal allografts for use in hernia repair, for ten years.
The new agreement includes a payment for exclusive distribution rights in the breast reconstruction market, and potentially two additional payments based on growth milestones in the hernia and breast reconstruction markets.
Brian Hutchison, chairman and chief executive officer of RTI, said: We are pleased to expand our relationship with Davol to include the exclusive distribution of human donated dermis for breast reconstruction applications. Since our merger with Tutogen last year, our hernia repair distribution has seen excellent growth, and we look forward to reaching more patients with safe, high quality biologic solutions in hernia and breast reconstruction with an industry leading distributor like Davol.